Intimation to Stock Exchange
2025-2026
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Intimation regarding Notice from GST Authority.
June 13, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Order for Drop of Proceedings under GST Act, 2017
June 12, 2025Reg 30 SEBI (LODR) - Analyst meet – scheduled on 17-06-2025 at 4.00 pm over VC.
June 12, 2025
2024-2025
Outcome of Board Meeting held on 22nd May, 2025
May 22, 2025Indoco Q4 revenues at ₹ 3,411 mn
May 22, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Reappointment of Cost Auditor
March 27, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Income Tax Assessment Order dated 26/03/2025
March 27, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Revised Disclosure pertaining to Order dated 20-02-2025 of GST Authority.
February 28, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Order dated 25-02-2025 respectively received from GST Authority.
February 25, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Order dated 20-02-2025 respectively received from GST Authority.
February 25, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Drop of proceedings vide Order dated 24-02-2025 against the SCN
February 25, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Revision in Credit Rating.
January 31, 2025Outcome of Board Meeting held on 21st January, 2025
January 21, 2025Indoco Q3 revenues at ₹ 3,649 mn
January 21, 2025Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Receipt of Warning Letter from USFDA for our facilities located at Goa Plant II & III
December 17, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst / Institutional Investor meet - Valorem CXO Meet (VIRTUAL)
December 10, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst meet - FRANKLIN TEMPLETON (VIRTUAL CALL)
November 28, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst meet - JM Financial India Conference 2024.
November 08, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst meet - Nirmal Bang Institutional Equities Investor Conference.
November 07, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Appointment of Senior Management Personnel - Mr. Vaibhav Sinha.
November 05, 2024Investor Presentation
October 24, 2024Outcome of Board Meeting held on 24th October, 2024
October 24, 2024Indoco Q2 revenues at ₹ 3,946 mn
October 24, 2024-
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - 77th AGM Proceedings
September 26, 2024 -
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst meet - DAM Capital Pharmaceutical
September 13, 2024 -
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Withdrawal of Show Cause Notice received from the Goods and Service Tax (GST) Authority
September 13, 2024 -
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst meet - DOLAT CAPITAL
September 12, 2024 -
Reg 30 SEBI (LODR) - Newspaper Advertisement post dispatch of Notice of 77th Annual General Meeting
September 03, 2024 -
Reg 30 & 34 SEBI (LODR) - Notice of the 77th Annual General Meeting (AGM) and Annual Report 2023-2024
September 02, 2024 -
Intimation of Book Closure & Record Date for payment of dividend and AGM.
August 30, 2024 -
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Analyst meet- Ashwamedh, Elara India Dialogue 2024.
August 28, 2024 -
Reg 30 SEBI (LODR) - Newspaper Advertisement prior to dispatch of Notice of 77th Annual General Meeting
August 28, 2024 -
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Notice received from the Goods and Service Tax (GST) Authority
August 23, 2024 -
Analyst meet - at the Emkay Confluence to be held on 12th August, 2024
August 7, 2024 Outcome of Board Meeting held on 23rd July, 2024
July 23, 2024Indoco revenues at ₹ 3942 mn
July 23, 2024
2023-2024
Outcome of Board Meeting held on 16th May, 2024
May 16, 2024Indoco's annual revenues grow by 7.6 %
May 16, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Cessation of Independent Directors
March 29, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - ESOP Allotment
March 29, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Grant of Options and RSUs
March 29, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Re-appointment of Auditors
March 29, 2024Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Intimation of Acquisition of Land.
March 12, 2024Reg 30 SEBI (LODR) – Investor conference – Antique Stock Broking Ltd. - 9th Flagship Investor Conference - Build India New India
February 6, 2024Reg 30 SEBI (LODR) - Analyst meet – Mr. Sampath Reddy - CIO of Bajaj Allianz & his team.
February 1, 2024Appointment of Independent Directors
January 23, 2024Outcome of Board Meeting held on 23rd January, 2024
January 23, 2024Indoco’s revenue grows 9% in Q3FY24
January 23, 2024-
Reg 30 SEBI (LODR) - Analyst meet Anand Rathi Annual Flagship Conference G-200 Summit / Nirmal Bang Conference.
November 01, 2023 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Update on USFDA Goa Plant I
October 19, 2023Outcome of Board Meeting held on 19th October, 2023
October 19, 2023Indoco’s profit grows 28 % Quarter on Quarter
October 19, 2023Proceedings of 76th Annual General Meeting of Indoco Remedies Limited
September 26, 2023Reg 30 SEBI (LODR)- Newspaper Advertisement post dispatch of Notice of 76th Annual General Meeting
September 2, 2023Reg 30 & 34 SEBI (LODR) - Notice of the 76th Annual General Meeting (AGM) and Annual Report 2022-2023
September 1, 2023Intimation of Book Closure & Record Date for payment of dividend and AGM
September 1, 2023Reg 30 SEBI (LODR)- Change in Senior Management Personnel
August 31, 2023Reg 30 SEBI (LODR) - Newspaper Advertisement prior to dispatch of Notice of 76th Annual General Meeting.
August 28, 2023Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Update on Intimation of fire accident in the premises of Waluj plant.
August 28, 2023Reg 30 SEBI (LODR) - Analyst meet Nirmal Bang Conference / Ashwamedh - Elara India Dialogue 2023
August 18, 2023Disclosure under Regulation 30 of SEBI LODR Regulations, 2015- Investor Meet at Emkay Confluence
August 12, 2023Disclosure under Regulation 30 of SEBI LODR Regulations, 2015- Corporate Guarantee to WRPL, subsidiary of the Company
August 12, 2023Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Update on Intimation of fire accident in the premises of Waluj plant.
August 04, 2023Outcome of Board Meeting held on 25th July, 2023
July 25, 2023Indoco revenues grew by 5 % in Q1FY24
July 25, 2023Analyst meet with Baroda BNP Paribas Mutual Fund/DSP Investment Manager along with Systematix Group – 26th June 2023.
June 23, 2023
2022-2023
Outcome of Board Meeting held on 23rd May, 2023
May 23, 2023Indoco revenues grow 9% for the Financial Year 2022-23
May 23, 2023USFDA Inspection at Indoco Remedies Limited's Plant II (Sterile Facility) and Plant III (OSD Facility) At Goa
March 01, 2023Intimation of Audio/Video recording of Conference organized by Dolat Capital Market Private Limited
February 21, 2023Intimation of Audio/Video recording of Investors Conference Call organized by Nirmal Bang
February 14, 2023Intimation of Schedule of Investors Conference on 6th February, 2023
February 03, 2023Intimation of Schedule of Investors Conference on 13th & 17th February, 2023
February 02, 2023Transcript of Earnings Conference Call for the quarter and nine months ended 31st December, 2022
January 31, 2023Intimation of audio recording of the earnings conference call Q3 2022-2023
January 25, 2023Grant of Options & RSUs under Indoco Remedies Limited Employee Stock Option Plan – 2022
January 25, 2023Outcome of Board Meeting held on 24th January, 2023
January 24, 2023Indoco's Net Revenues grow at 18 % in Q3FY23
January 24, 2023USFDA inspection at Indoco Remedies Limited’s Solid Oral Formulation Facility (Plant 1) at Goa
January 23, 2023Intimation of Earnings Conference Call on unaudited financial results for quarter and nine months ended 31st December, 2022
January 17, 2023Notice of Board Meeting - Quarter ended December 31, 2022
January 11, 2023Outcome of Board Meeting dated 10th November, 2022
November 10, 2022PAT grows 29% in Q2 over Q1 FY 2022-23
November 10, 2022Revised Schedule of Con Call Meeting
November 08, 2022Intimation of Board Meeting – Unaudited Financial Results for the quarter & half year ended September 30, 2022
October 21, 2022Reconciliation of Share Capital Report for the quarter ended 30th September 2022
October 13, 2022Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
October 13, 2022Quarterly Statement of Investor Complaints Regulation 13(3) of SEBI (LODR) Regulations, 2015
October 11, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
October 06, 2022Shareholders approves Indoco Remedies Limited Employee Stock Option Plan – 2022
September 23, 2022Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Reappointment of Director & Auditor in the 75th AGM
September 23, 2022Proceedings of 75th Annual General Meeting of Indoco Remedies Limited
September 22, 2022Disclosure under Regulation 30 of LODR Regulations 2015
Indoco's AnaCipher CRO clears USFDA inspection with Zero 483s
September 19, 2022Notice of the 75th Annual General Meeting of Indoco Remedies Limited
August 22, 2022Intimation of Book closure and record date for payment of dividend and AGM
August 22, 2022Audio recording of Conference Call held on August 09, 2022
August 10, 2022Sustained performance in Q1FY 2022-23
August 09, 2022Outcome of Board Meeting dated 09th August, 2022
August 09, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
August 03, 2022Schedule of Con Call Meeting
July 23, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
July 21, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
July 19, 2022Intimation of Board Meeting – Unaudited Financial Results for the quarter ended June 30, 2022
July 15, 2022Corporate governance Report ended 30th June, 2022
July 07, 2022Trading Window Closure
June 30, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
June 15, 2022
2021-2022
Intimation of Schedule of Analyst / Institutional Investors Meet
May 30, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
May 27, 2022Audio recording of Conference Call held on May 17, 2022
May 17, 2022Outcome of Board Meeting dated 17th May, 2022
May 17, 2022Indoco’s PAT jumps 62% in Q4FY22
May 17, 2022Schedule of Con Call Meeting
May 06, 2022Board Meeting for Approval of Audited Accounts
April 22, 2022Disclosure under Regulation 30 of LODR Regulations 2015 Indoco Remedies receives USFDA approval for Lacosamide Injection USP
April 08, 2022Compliance Report on Corporate Governance {Regulation 27(2)}
April 05, 2022Disclosure under Regulation 30 of LODR Regulations 2015
Indoco Remedies receives USFDA approval for Lacosamide Tablets
March 22, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 18, 2022Intimation under Regulation 30 of SEBI (LODR) Regulations 2015 Incorporation of a Wholly Owned Subsidiary Company
February 16, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 16, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 15, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 15, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 11, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
February 09, 2022Transcript of Conference Call held on February 02, 2022
February 09, 2022Audio recording of Conference Call held on February 02, 2022
February 02, 2022Publication of Un-Audited Financial Results for the Quarter and Nine Months ended 31st December, 2021
February 02, 2022Submission of Standalone & Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2021
February 01, 2022Indoco’s PAT jumps 31 % in Q3FY22
February 01, 2022Rescheduling of Con Call Meeting
January 29, 2022Intimation of Board Meeting – Unaudited Financial Results for the quarter ended December, 31, 2021
January 04, 2022Intimation of Schedule of Analyst / Institutional Investors Meet
December 07, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
November 23, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
November 22, 2021Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (LODR) Regulations, 2015 (Listing Regulations)
November 15, 2021Submission of Standalone & Consolidated Unaudited Financial Results for the Quarter and Half year ended 30th September, 2021
November 02, 2021Indoco's EBIDTA jumps 43 % in Q2FY22
November 02, 2021Schedule of Con Call Meeting
October 22, 2021Intimation of Board Meeting - Unaudited Financial Results for the quarter/half year ended September 30, 2021
October 11, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
September 08, 2021Intimation of Schedule of Analyst / Institutional Investors Meet
September 06, 2021Newspaper Advertisement - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
September 04, 2021Indoco's Clinical Research Organization – AnaCipher receives accreditation from UKMHRA
August 27, 2021Submission of Standalone & Consolidated Unaudited Financial Results for the First quarter ended 30th June, 2021
August 11, 2021Indoco's revenues grow at 43 %, EBIDTA jumps 78 % in Q1FY22
August 11, 2021Schedule of Con Call Meeting
July 28, 2021Credit Rating by ICRA
July 23, 2021
2020-2021
Indoco's Revenue Growth at 12%, EBIDTA Jumps 64% in Q4FY21
May 25, 2021Schedule of Con Call Meeting
May 19, 2021Board Meeting for Approval of Audited Accounts
May 03, 2021Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
March 09, 2021EBIDTA Jumps 71%, Revenue Growth @ 18% for Indoco in Q3FY21
February 09, 2021Schedule of Con Call Meeting
January 22, 2021Intimation of Board Meeting – Unaudited Financial Results for the quarter ended December, 31, 2020
January 13, 2021Closure of Trading Window
December 31, 2020Indoco wins major tenders in Germany for Allopurinol Tablets
December 08, 2020EBIDTA Doubles, Revenue Growth of 13% for Indoco in Q2FY21
November 06, 2020Schedule of Con Call Meeting
Otober 22, 2020Intimation of Board Meeting – Unaudited Financial Results for the quarter/half year ended September, 30, 2020
Otober 19, 2020Appointment of Mr. Abhijit Yashwant Gore as an Additional Independent Director of the Company
Otober 02, 2020Closure of Trading Window
September 30, 2020Retirement of Independent Director
September 30, 2020Indoco launches Fevindo 400 (Favipiravir 400mg Tablets)
September 26, 2020Indoco receives USFDA approval for Apixaban Tablets
September 14, 2020Disclosure Under Regulation 30 of LODR Regulations 2015 Credit Rating by ICRA
September 10, 2020Notice for the Seventy Third Annual General Meeting
September 01, 2020EBIDTA Doubles, Sales Grow for Indoco in Q1FY21
August 11, 2020Indoco receives USFDA approval for Olanzapine Tablets
August 06, 2020Schedule of Con Call Meeting
July 28, 2020Intimation of Board Meeting – Unaudited Financial Results for the quarter ended June 30, 2020
July 10, 2020